株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肺炎桿菌(肺炎クレブシエラ)感染症:パイプライン製品の分析

Klebsiella pneumoniae Infections - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 251627
出版日 ページ情報 英文 108 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
肺炎桿菌(肺炎クレブシエラ)感染症:パイプライン製品の分析 Klebsiella pneumoniae Infections - Pipeline Review, H2 2016
出版日: 2016年10月19日 ページ情報: 英文 108 Pages
概要

肺炎桿菌(肺炎クレブシエラ)とはグラム陰性菌であり、肺炎桿菌感染症はこの菌が肺に入ることによって引き起こされます。この感染症は、糖尿病や慢性肺疾患、慢性アルコール依存症などの基礎疾患を持つ患者の間でよく見られ、多くの場合、免疫系の弱った入院患者が院内感染によって発症します。壊死、炎症、出血、悪寒、高熱、頭痛、胸の痛みなどの症状があり、治療には、抗生剤の利用や衛生的な生活などがあります。

当レポートでは、世界における肺炎桿菌(肺炎クレブシエラ)感染症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

肺炎桿菌(肺炎クレブシエラ)感染症の概要

治療薬の開発

  • 肺炎桿菌(肺炎クレブシエラ)感染症向けパイプライン製品:概要
  • 肺炎桿菌(肺炎クレブシエラ)感染症向けパイプライン製品:比較分析

肺炎桿菌(肺炎クレブシエラ)感染症:開発中の治療薬:企業別

肺炎桿菌(肺炎クレブシエラ)感染症:開発中の治療薬:大学・研究機関別

肺炎桿菌(肺炎クレブシエラ)感染症:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

肺炎桿菌(肺炎クレブシエラ)感染症:開発中の製品:企業別

肺炎桿菌(肺炎クレブシエラ)感染症:開発中の製品:大学・研究機関別

肺炎桿菌(肺炎クレブシエラ)感染症:治療薬開発に従事している企業

  • Arsanis Biosciences GmbH
  • Cellceutix Corporation
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • F. Hoffmann-La Roche Ltd.
  • FOB Synthesis, Inc.
  • Melinta Therapeutics, Inc
  • Merck & Co., Inc.
  • MicuRx Pharmaceuticals, Inc.
  • Nosopharm SAS
  • Pfizer Inc.
  • Phico Therapeutics Limited
  • Procarta Biosystems Limited
  • Sarepta Therapeutics, Inc.
  • シオノギ製薬
  • Soligenix, Inc.
  • 大日本住友製薬
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.
  • Theraclone Sciences, Inc.
  • Varinel, Inc.

肺炎桿菌(肺炎クレブシエラ)感染症:治療薬の評価

  • 単剤治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections
  • ASN-300
  • CB-027
  • CB-618
  • CC-1807
  • CTIX-1278
  • Debio-1454
  • dusquetide
  • FSI-1671
  • FSI-1686
  • GN snare
  • IBN-1
  • Klebsiella pneumoniae vaccine
  • Klebsiella pneumoniae vaccine
  • Monoclonal Antibody for Klebsiella Pneumoniae Infections
  • MRX-V
  • NOSO-95179
  • Onc-72
  • PMX-100
  • PMX-1091
  • PMX-1142
  • PMX-229
  • PMX-633
  • pneumonia vaccine
  • pneumonia vaccine
  • PT-4
  • RX-05
  • RXP-792
  • RXP-873
  • S-649266
  • SM-295291
  • SM-369926
  • Small Molecule for Gram-Negative Nosocomial Infections
  • Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections
  • Small Molecules for Bacterial Infections
  • Small Molecules for Klebsiella pneumoniae Infections
  • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections
  • Small Molecules to Inhibit DHFR for Infectious Diseases
  • Synthetic Peptide for Gram-Negative Bacterial Infections
  • Synthetic Peptide for Klebsiella Pneumoniae Infections
  • TP-076
  • TP-6076
  • VAR-10100 - Drug Profile
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8541IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H2 2016, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 22 and 14 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Klebsiella pneumoniae Infections.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Klebsiella pneumoniae Infections Overview
  • Therapeutics Development
    • Pipeline Products for Klebsiella pneumoniae Infections - Overview
    • Pipeline Products for Klebsiella pneumoniae Infections - Comparative Analysis
  • Klebsiella pneumoniae Infections - Therapeutics under Development by Companies
  • Klebsiella pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes
  • Klebsiella pneumoniae Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Klebsiella pneumoniae Infections - Products under Development by Companies
  • Klebsiella pneumoniae Infections - Products under Investigation by Universities/Institutes
  • Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
    • Appili Therapeutics Inc
    • Arsanis, Inc.
    • Cellceutix Corporation
    • Debiopharm International SA
    • Evaxion Biotech ApS
    • F. Hoffmann-La Roche Ltd.
    • FOB Synthesis, Inc.
    • Melinta Therapeutics, Inc
    • Merck & Co., Inc.
    • MicuRx Pharmaceuticals, Inc.
    • Nosopharm SAS
    • Peptilogics, Inc.
    • Pfizer Inc.
    • Phico Therapeutics Limited
    • Procarta Biosystems Limited
    • Sarepta Therapeutics, Inc.
    • Shionogi & Co., Ltd.
    • Soligenix, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Syntiron LLC
    • Tetraphase Pharmaceuticals Inc.
    • Varinel, Inc.
  • Klebsiella pneumoniae Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile
    • ASN-300 - Drug Profile
    • ATI-1503 - Drug Profile
    • CA-824 - Drug Profile
    • CB-027 - Drug Profile
    • CB-618 - Drug Profile
    • CC-1807 - Drug Profile
    • CTIX-1278 - Drug Profile
    • Debio-1454 - Drug Profile
    • dusquetide - Drug Profile
    • FSI-1671 - Drug Profile
    • FSI-1686 - Drug Profile
    • GNEG SNARE - Drug Profile
    • IBN-1 - Drug Profile
    • klebsiella pneumonia vaccine - Drug Profile
    • Klebsiella pneumoniae vaccine - Drug Profile
    • Klebsiella pneumoniae vaccine - Drug Profile
    • Klebsiella pneumoniae vaccine - Drug Profile
    • mirandamycin - Drug Profile
    • MRX-V - Drug Profile
    • NOSO-95179 - Drug Profile
    • Onc-72 - Drug Profile
    • Peptides for Infectious Diseases - Drug Profile
    • PMX-100 - Drug Profile
    • PMX-1091 - Drug Profile
    • PMX-1142 - Drug Profile
    • PMX-229 - Drug Profile
    • PMX-633 - Drug Profile
    • PT-4 - Drug Profile
    • RX-05 - Drug Profile
    • RXP-873 - Drug Profile
    • S-649266 - Drug Profile
    • SM-295291 - Drug Profile
    • SM-369926 - Drug Profile
    • Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
    • Small Molecules for Bacterial Infections - Drug Profile
    • Small Molecules for Bacterial Infections - Drug Profile
    • Small Molecules for Klebsiella pneumoniae Infections - Drug Profile
    • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
    • Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
    • SPR-741 - Drug Profile
    • Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile
    • TP-6076 - Drug Profile
    • VAR-10100 - Drug Profile
  • Klebsiella pneumoniae Infections - Dormant Projects
  • Klebsiella pneumoniae Infections - Discontinued Products
  • Klebsiella pneumoniae Infections - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Klebsiella pneumoniae Infections, H2 2016
  • Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Arsanis, Inc., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Cellceutix Corporation, H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA , H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Evaxion Biotech ApS, H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by FOB Synthesis, Inc., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Merck & Co., Inc., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Peptilogics, Inc., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Pfizer Inc., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Limited, H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Procarta Biosystems Limited, H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Soligenix, Inc., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016
  • Klebsiella pneumoniae Infections - Pipeline by Varinel, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Klebsiella pneumoniae Infections - Dormant Projects, H2 2016
  • Klebsiella pneumoniae Infections - Dormant Projects (Contd..1), H2 2016
  • Klebsiella pneumoniae Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Klebsiella pneumoniae Infections, H2 2016
  • Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top